Compound Comparison
GLP-1S vs. GLP-2T: Key Differences for Researchers
Two of the most studied GLP-1 receptor agonists in peptide research are GLP-1S (GLP-1S at Rapid Research Labs) and GLP-2T (GLP-2T). While both activate the GLP-1 receptor, their pharmacological profiles diverge significantly. This comparison is designed to help researchers choose the right compound for the right experimental question.
Receptor Pharmacology: Where They Differ
GLP-1S is a selective GLP-1 receptor agonist. It was engineered from human GLP-1 with fatty acid modification to extend its half-life. It binds with high affinity to GLP-1 receptors expressed in pancreatic beta cells, the hypothalamus, the gut, and elsewhere.
GLP-2T is a dual GLP-1 / GIP agonist. GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone produced in the small intestine. By activating both the GLP-1 receptor and the GIP receptor simultaneously, GLP-2T engages two distinct incretin pathways in a single molecule.
| Property | GLP-1S | GLP-2T |
|---|---|---|
| Receptor Targets | GLP-1R | GLP-1R + GIPR |
| Mechanism Class | Selective agonist | Dual agonist |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ | C₂₂₅H₃₄₈N₄₈O₆₈ |
| CAS Number | 910463-68-2 | 2023788-19-2 |
| Purity (Rapid Research Labs) | ≥99% | ≥99% |
| Available Sizes | 5mg, 10mg, 15mg | 5mg, 10mg, 15mg |
Research Applications
When to Use GLP-1S
GLP-1S is the appropriate choice when your research question is specifically about GLP-1 receptor signaling. Its selectivity makes it a cleaner tool for isolating GLP-1 pathway effects without GIP receptor confounding. It is widely used in metabolic research, glucose homeostasis models, and metabolic-signaling studies.
When to Use GLP-2T
GLP-2T is the better choice when you want to study incretin synergy — the combined effect of GLP-1 and GIP co-activation. It is particularly relevant for research investigating adipose tissue biology, since GIP receptors are highly expressed in adipocytes. Studies comparing GLP-1-only vs. dual-agonist effects commonly pair these two compounds.
Structural Considerations
GLP-2T's size (C₂₂₅H₃₄₈N₄₈O₆₈, MW ~4813 Da) is notably larger than GLP-1S (C₁₈₇H₂₉₁N₄₅O₅₉, MW ~4114 Da). Preparation and handling should follow an assay-specific laboratory protocol validated for each compound.
For Triple-Receptor Research
If your research focus extends to glucagon receptor (GCGR) co-activation alongside GLP-1 and GIP, consider also evaluating our GLP-3R (Retatrutide) — a GLP-1 / GIP / GCG triple agonist available in 5mg, 10mg, and 15mg vials.
Frequently Asked Questions
What is the main mechanistic difference between GLP-1S and GLP-2T?
GLP-1S is a selective GLP-1 receptor agonist. GLP-2T is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. The addition of GIP receptor activity is the primary pharmacological distinction.
Which peptide produces stronger effects in metabolic research models?
Preclinical data suggest GLP-2T's dual mechanism may produce more pronounced effects on glucose homeostasis and adipose tissue reduction compared to selective GLP-1 agonism alone. However, the optimal choice depends on the specific receptor pathway your research is investigating.
Can GLP-1S and GLP-2T be used in the same assay for comparison?
Yes, they are commonly paired in side-by-side in-vitro experiments to isolate the contribution of GIP receptor co-activation. Ensure equal molar concentrations when making direct comparisons in cell-based assays.